Similar articles

• [Molecular-based treatment concepts in advanced pancreatic cancer].

  Boeck S, Moosmann N, Stemmler HJ, Heinemann V. Boeck S, et al. Dtsch Med Wochenschr. 2007 Apr 13;132(15):818-22. doi: 10.1055/s-2007-973627. Dtsch Med Wochenschr. 2007. PMID: 17427093 Review. German. No abstract available.
• Recent updates on the role of chemotherapy in pancreatic cancer.

  Burris HA 3rd. Burris HA 3rd. Semin Oncol. 2005 Aug;32(4 Suppl 6):S1-3. doi: 10.1053/j.seminoncol.2005.06.022. Semin Oncol. 2005. PMID: 16143160 Review.
• A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.

  Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. Ko AH, et al. Invest New Drugs. 2012 Aug;30(4):1597-606. doi: 10.1007/s10637-011-9691-8. Epub 2011 Jun 1. Invest New Drugs. 2012. PMID: 21629990 Clinical Trial.
• Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.

  Boeck S, Heinemann V. Boeck S, et al. J Clin Oncol. 2008 Mar 1;26(7):1178-9; author reply 1179. doi: 10.1200/JCO.2007.15.3304. J Clin Oncol. 2008. PMID: 18309957 No abstract available.
• The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.

  Boeck S, Heinemann V. Boeck S, et al. Future Oncol. 2008 Feb;4(1):41-50. doi: 10.2217/14796694.4.1.41. Future Oncol. 2008. PMID: 18240999 Review.